SpyGlass Pharma (SGP) Reports $24.3M Q3 Net Loss; Holds $215.8M in Cash

SpyGlass Pharma reported a Q3 2026 net loss of $24.3M, versus $9.8M in Q3 2025, and cash, cash equivalents and short-term investments of $215.8M at September 30, 2026. It acquired AVS for approximately $13M in cash.Material DetailsContext by AI AnalystThis is a late-stage clinical company's quarter…